Essex Bio-Technology Limited (HKG:1061)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.190
+0.020 (0.63%)
Apr 29, 2026, 4:08 PM HKT
-27.50%
Market Cap 1.81B
Revenue (ttm) 1.81B
Net Income (ttm) 318.09M
Shares Out 567.01M
EPS (ttm) 0.56
PE Ratio 5.69
Forward PE 5.60
Dividend 0.14 (4.42%)
Ex-Dividend Date May 28, 2026
Volume 203,000
Average Volume 468,300
Open 3.160
Previous Close 3.170
Day's Range 3.140 - 3.260
52-Week Range 3.100 - 6.120
Beta 0.02
RSI 35.57
Earnings Date Mar 23, 2026

About Essex Bio-Technology

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate,... [Read more]

Sector Healthcare
Founded 1990
Employees 1,426
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1061
Full Company Profile

Financial Performance

In 2025, Essex Bio-Technology's revenue was 1.81 billion, an increase of 8.62% compared to the previous year's 1.67 billion. Earnings were 318.09 million, an increase of 3.54%.

Financial Statements

News

There is no news available yet.